Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2275PDF: 1834HTML: 836 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2560PDF: 821HTML: 1745 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1466HTML: 641PDF: 876 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2189PDF: 1349HTML: 3513 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2065PDF: 1585HTML: 803 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2928PDF: 1052HTML: 5639 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2569PDF: 1734HTML: 518 -
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS
2682PDF: 900HTML: 2131 -
HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
2153PDF: 803HTML: 3255 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3296PDF: 965HTML: 3011 -
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2301PDF: 850HTML: 1697Figure 1: 224Table 1: 236 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2738PDF: 791HTML: 2322 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1356PDF: 1083HTML: 425 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4458PDF: 1799HTML: 1122 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3132PDF: 1644HTML: 365 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3779PDF: 934HTML: 6871 -
ASSOCIATION OF BASELINE PLATELET COUNT WITH COMPLETE REMISSION, SEVERE BLEEDING, AND 24-MONTH OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY
53PDF: 34Suppl. Files: 7Html: 7Html Suppl. Files: 7 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7819PDF: 2481HTML: 2115Table 1.: 246Table 2.: 257Table 3.: 237Table 4.: 232 -
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
3396PDF: 989HTML: 2990 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1472PDF: 943HTML: 249 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
3037PDF: 898HTML: 6611Untitled: 262Untitled: 218Untitled: 234Untitled: 247 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
1945PDF: 1037HTML: 243 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
2288PDF: 752HTML: 2144Untitled: 247Untitled: 170Untitled: 201Untitled: 174Untitled: 192Untitled: 200Untitled: 205 -
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia
1743PDF: 539HTML: 348 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1523PDF: 1370HTML: 112 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
4051PDF: 779HTML: 1885 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
2058PDF: 861HTML: 255 -
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1855PDF: 611HTML: 349
1 - 50 of 50 items







